A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Acerta Pharma BV
Acerta Pharma BV
Nkarta, Inc.
City of Hope Medical Center
Nurix Therapeutics, Inc.
Verismo Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Calibr, a division of Scripps Research
City of Hope Medical Center
British Columbia Cancer Agency
Novartis
City of Hope Medical Center
AbbVie
Memorial Sloan Kettering Cancer Center
Hackensack Meridian Health
Ohio State University Comprehensive Cancer Center
Nurix Therapeutics, Inc.
MEI Pharma, Inc.
Massachusetts General Hospital
Atara Biotherapeutics
Cedars-Sinai Medical Center
Eli Lilly and Company
City of Hope Medical Center
Medical College of Wisconsin
Ascentage Pharma Group Inc.
Newave Pharmaceutical Inc
Schrödinger, Inc.
Mayo Clinic
LTZ Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Prelude Therapeutics
AbbVie
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
University of Colorado, Denver
OncoNano Medicine, Inc.
Carna Biosciences, Inc.
Sana Biotechnology
National Cancer Institute (NCI)
City of Hope Medical Center
PeproMene Bio, Inc.
National Cancer Institute (NCI)
University of Arizona
Case Comprehensive Cancer Center
Incyte Corporation
City of Hope Medical Center
City of Hope Medical Center
Accutar Biotechnology Inc
Sana Biotechnology
Iksuda Therapeutics Ltd.